Zacks Investment Research
17 Sept 2026, 13:51 UTC · 1h ago
Verdict
Headline takes no side. We score CTKB −0.30 across two claims — moderately bearish.
−0.30moderately bearish
More negative than 74% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 1 new · 1 priced in
The Zacks Consensus Estimate for Cytek Biosciences' current quarter has moved from $0.03 per share to a break-even point over the last 60 days.
Priced inanalysis of estimates over last 60 days
So whatA 100% drop in EPS expectations for the current quarter may lead to a downward revision of the company's forward P/E multiple.
More negative than 80% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
The October 16, 2026 $02.50 Put option for Cytek Biosciences exhibited some of the highest implied volatility of all equity options on September 17.
Newstated as happening "today" (Sep 17)
So whatHigh IV suggests the market expects a significant price swing within the next 30 days.
More positive than 54% of claims this week
Which stocks this story touches
More negative than 74% of ticker scores this week
The company has a 'Hold' rank, is in a bottom-tier industry, and has seen downward analyst estimate revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
7h ago
+2.5%
Price is moving against the score
$5.05 vs $4.93 close before publication (Sep 16) · not market-adjusted
CTKB chart →
